We deliver RNases that cut dsRNA like restriction enzymes cut DNA

Model of eRNase enzyme in a complex with dsRNA substrate.

DNA restriction endonucleases, widely used in molecular biology, are sequence dependent enzymes able to recognize and cleave specific sites in double-stranded DNA. In turn, there is a paucity of enzymes able to cleave RNA in a similar manner.

Our mission is to overcome the above disadvantages and deliver new molecular biology tools: enzymes that cut specific sequences in double stranded RNA molecules.

We have already introduced to the market eRNase1 enzyme which can specifically recognize and cleave a four nucleotide sequence in dsRNA. In addition to eRNase1, we are developing a new group of engineered enzymes that act on various RNA targets. We are also exploring potential applications of the enzymes in a wide range of RNA manipulation techniques and novel technologies derived from them. Our data demonstrate that these RNase enzymes are promising tools for various applications involving RNA.

 


Applications

RNA-engineering technologies and gene-silencing methods 

The eRNase1 enzyme can be used to produce defined, functional dsRNA molecules by excising them from a longer precursor (e.g., long RNA molecule transcribed in vitro or in vivo). This is particularly useful in enzymatic preparation of functional dsRNA molecules, e.g. small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) applied in RNA interference (RNAi). RNAi molecules are currently widely used in research and are considered as new generation therapeutics.

eRNase1 can also be used in ssRNA-engineering technologies. eRNase1 efficiently cleaves desired ssRNA molecules upon annealing of a complementary ribo-oligonucleotide containing the eRNase1 target sequence.

Large-scale production of RNA for experimental research

Our technology allows for obtaining RNA molecules with defined sequences, structures and the 5′ and 3′ ends which can be further used in RNA crystallography and nanotechnology. Additionally, the advantage of the proposed solution is the ability to generate RNA molecules with homogeneous ends. The technology eliminates limitations of currently available solutions e.g. constraints of chemical synthesis of ribo-oligonucleotides to the maximum length of 80 nucleotides.

RNA structure research

eRNase1 can be used to experimentally confirm RNA secondary structure predictions.


References

Sequence-specificific cleavage of dsRNA by Mini-III RNase
D. Glow, D. Pianka, A. A. Sulej, L. P. Kozlowski, J. Czarnecka, G. Chojnowski, K. J. Skowronek and J. M. Bujnicki; Nucleic Acids Research, 2015, Vol. 43, No. 5, 2864-2873

Identification of protein structural elements responsible for the diversity of sequence preferences among Mini-III RNases
D. Glow, M. Kurkowska, J. Czarnecka, K. Szczepaniak, D. Pianka, V. Kappert, J. M. Bujnicki and K. J. Skowronek; Scientific Reports, 2016, Vol. 6:38612.

Sequence-specific endoribonucleases
D. Glow, M. Nowacka, K. J. Skowronek, J. M. Bujnicki; Postepy Biochemii, 2016, Vol. 62(3), 303-314


IP Rights

eRNase is protected worldwide by patent family including patents/pending patents no:

EP2718431 B1
EP2718431A1
US9238805
US20140087427
CA2837143A1
CA2837143C
CN103764821A
CN103764821B
WO2012169917A1

 

© 2018 Futurenzymes Ltd. All Rights Reserved.